A panel of breast oncologists highlight their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.

Treatment algorithms used in clinical practice by breast oncologists to best approach and subsequently treat patients with HER2-positive metastatic breast cancer.

Key takeaways from updates to the HER2CLIMB study in HER2-positive metastatic breast cancer.

Reactions to presentations from ESMO 2021 that demonstrated the potential of various new treatment approaches for use in HER2-positive metastatic breast cancer.

Recommendations regarding how to best treat a patient with HER2-positive metastatic breast cancer who has previously received multiple lines of therapy, including T-DM1.

Variables that affect second-line treatment decisions in HER2-positive metastatic breast cancer.

Expectations regarding future treatment guidelines in HER2-positive metastatic breast cancer as a result of therapeutic advances.

A small panel of breast oncologists recognize growing interest in understanding the role of HER2 expression in metastatic breast cancer.

Exciting therapeutic strategies in the HER2-positive metastatic breast cancer space that demonstrate potential in addressing gaps in treatment.

Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.

An expert breast medical oncologist discusses recent changes to HER2+ mBC treatment guidelines due to key findings from the DESTINY-Breast03 trial.

Insights concerning the selection of effective treatment approaches for patients with HER2+ mBC presenting with brain metastases and other complications.

Discussion centered around the latest data and guideline updates, and how these changes affect therapy sequencing in the first, second, and third lines of treatment.

Clinically relevant advice for the monitoring and management of pulmonary complications in patients with HER2+ mBC.

Dr. Neil M. Iyengar closes the discussion with preliminary results from a phase I study, thoughts on use of biosimilars, and other in-progress trials of interest.